ASCO 2025 | DANTE: evaluating 1 vs 2 years of anti-PD-1 therapy in metastatic melanoma
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the Phase III DANTE trial (ISRCTN15837212), which compared 1 year versus at least 2 years of first-line anti-PD-1-based immunotherapy in metastatic melanoma. Although a shorter duration appeared non-inferior for progression-free survival, early trial closure limited statistical power. Findings support continued use of 2-year therapy as standard while ongoing analyses further explore quality of life, toxicity, and cost-effectiveness outcomes. The PET‐Stop trial (NCT04462406) will subsequently assess biomarkers seen on PET/CT imaging to stop therapy in this setting. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
